Company profile
HuniLife Biotechnology, Inc.
Privately held: no public share price (Taiwan-based biopharmaceutical company (Taipei, founded 2013) developing therapeutic antibodies (HuL001, HuL003). No public listing found; private. Sources: https://clinicaltrials.gov/study/NCT07210047 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://api.gleif.org/api/v1/lei-records/254900ESD9GZFY66OR92 ; https://api.gleif.org/api/v1/lei-records/549300NIGKDV9203Q946 ; https://api.gleif.org/api/v1/lei-records/5493007DSIFXCC6J0N24 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | ENO1 (alpha-enolase 1)Monoclonal antibody | Multiple Myeloma |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.